Evidence map›Paper›PMID 42206644›Full record

ReviewJournal of immunology research2026

Research Progress on the Mechanism of Ginsenoside Rg1 in Inflammatory Bowel Disease.

Dandan Liang, Shaolei Yang, Dehuai Jing, Guangxi Zhou, Fengqin Zhu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dandan LiangClinical Medical College of Jining Medical University, Jining Medical University, Jining, Shandong, China, jnmc.edu.cn.
Shaolei YangClinical Medical College of Jining Medical University, Jining Medical University, Jining, Shandong, China, jnmc.edu.cn.
Dehuai JingDepartment of Gastroenterology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, China, jnmc.edu.cn.
Guangxi ZhouDepartment of Gastroenterology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, China, jnmc.edu.cn.ORCID https://orcid.org/0000-0002-7803-605X
Fengqin ZhuDepartment of Gastroenterology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, China, jnmc.edu.cn.ORCID https://orcid.org/0000-0002-2678-5606

Funding

Development plan of Medicine and Health Science and Technology in Shandong Province 202503030856National Natural Science Foundation of China 82200591National Natural Science Foundation of China 82270562Natural Science Foundation of Shandong Province ZR2024MH282Natural Science Foundation of Shandong Province ZR2025MS1260TCM Science and Technology Development Plan of Shandong Province M20254301
6 · The paper itself

Abstract

Inflammatory bowel disease (IBD), a chronic intestinal inflammatory disorder, has witnessed a rising incidence globally. At present, the primary therapeutic approaches for IBD, such as aminosalicylic acid, glucocorticoids, immunosuppressants, and biologics, often entail notable side effects and limited efficacy. Traditional Chinese medicines (TCMs), particularly ginsenosides, have shown promise in the treatment of IBD. Ginsenoside Rg1 (G-Rg1), a characteristic constituent of ginsenosides, exerts a therapeutic impact on IBD. This review primarily elaborates on how G-Rg1 can restore the equilibrium of inflammatory and anti-inflammatory factors within the intestinal milieu. It achieves this by modifying the structure and metabolism of the intestinal flora, reorganizing the tight junction proteins of the intestinal barrier, and regulating the interplay between signaling pathways and immune cells, ultimately attaining the effect of alleviating IBD.

Indexed as

Anti-Inflammatory AgentsGinsenosidesInflammatory Bowel DiseasesAnimalsGastrointestinal MicrobiomeHumansIntestinal Barrier FunctionIntestinal MucosaSignal TransductionAnti-Inflammatory Agentsginsenoside Rg1Ginsenosidesginsenoside Rg1gut microbiotaimmune cellsinflammatory bowel diseaseintestinal mucosal barrier

Identifiers

PMID42206644
PMCPMC13217393

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.